Neurocrine Biosciences (CH:NB3)
NASDAQ:NB3
Total Valuation
Neurocrine has a market cap or net worth of CHF13.38B. The enterprise value is $16.13B.
Market CapCHF13.38B
Enterprise Value$16.13B
Share Statistics
Neurocrine has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders1.14%
Owned by Institutions21.99%
Financial Efficiency
Neurocrine’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 10.80%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)10.80%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee1.59M
Profits Per Employee265.89K
Employee Count1,800
Asset Turnover0.62
Inventory Turnover0.76
Valuation Ratios
The current PE Ratio of Neurocrine is 24.5. Neurocrine’s PEG ratio is 0.71.
PE Ratio24.5
PS Ratio4.93
PB Ratio4.34
Price to Fair Value4.34
Price to FCF18.85
Price to Operating Cash Flow19.10
PEG Ratio0.71
Income Statement
In the last 12 months, Neurocrine had revenue of 2.86B and earned 478.60M in profits. Earnings per share was 4.81.
Revenue2.86B
Gross Profit2.81B
Operating Income619.10M
Pretax Income705.40M
Net Income478.60M
EBITDA666.60M
Earnings Per Share (EPS)4.81
Cash Flow
In the last 12 months, operating cash flow was 863.70M and capital expenditures -32.40M, giving a free cash flow of 831.30M billion.
Operating Cash Flow863.70M
Free Cash Flow831.30M
Free Cash Flow per Share10.00T>
Dividends & Yields
Neurocrine pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Neurocrine upcoming earnings date is Aug 4, 2026, After Close (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 4, 2026
Ex-Dividend Date―
Financial Position
Neurocrine as a current ratio of 3.39, with Debt / Equity ratio of 11.92%
Current Ratio3.39
Quick Ratio3.30
Debt to Market Cap0.00
Net Debt to EBITDA-0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neurocrine has paid 226.80M in taxes.
Income Tax226.80M
Effective Tax Rate0.32
Enterprise Valuation
Neurocrine EV to EBITDA ratio is 20.72, with an EV/FCF ratio of 18.45.
EV to Sales4.83
EV to EBITDA20.72
EV to Free Cash Flow18.45
EV to Operating Cash Flow17.65
Balance Sheet
Neurocrine has CHF1.32B in cash and marketable securities with CHF406.20M in debt, giving a net cash position of CHF910.00M billion.
Cash & Marketable SecuritiesCHF1.32B
Total DebtCHF406.20M
Net CashCHF910.00M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF32.69
Margins
Gross margin is 98.17%, with operating margin of 21.64%, and net profit margin of 16.73%.
Gross Margin98.17%
Operating Margin21.64%
Pretax Margin24.66%
Net Profit Margin16.73%
EBITDA Margin23.30%
EBIT Margin22.25%
Analyst Forecast
The average price target for Neurocrine is CHF153.76, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF153.76
Price Target Upside― Downside
Analyst ConsensusStrong Buy
Analyst Count24
Revenue Growth Forecast―
EPS Growth Forecast―